TS-121

TS-121 is an orally active, selective vasopressin V1B receptor antagonist which is under development by Taisho Pharmaceutical for the adjunctive treatment of major depressive disorder.[1][2] As of May 2017, it is in phase II clinical trials for this indication.[1][2]

TS-121
Clinical data
Other namesTS-1211
Routes of
administration		By mouth

See also

References
  1. "TS 121 - AdisInsight".
  2. "New Drug Pipeline - Taisho Pharmaceutical Holdings".



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.